CSIMarket
 


Adverum Biotechnologies Inc   (ADVM)
Other Ticker:  
 

Adverum Biotechnologies Inc 's Working Capital Ratio

ADVM's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2023, Working Capital Ratio deteriorated to 4.13 below Adverum Biotechnologies Inc 's average Working Capital Ratio.

Within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Working Capital Ratio than Adverum Biotechnologies Inc in forth quarter 2023. While Working Capital Ratio total ranking has improved so far during the IV Quarter 2023 to 625, from total ranking in the third quarter 2023 at 1104.

Explain Working Capital Ratio
How much in Current Assets ADVM´s has?
What is the value of ADVM´s Current Liabilities?


ADVM Working Capital Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change -22.74 % 0.82 % 45.39 % 99.99 % 51.25 %
Y / Y Current Assets Change -46.08 % -41.57 % -40.19 % -39.71 % -39.9 %
Working Capital Ratio MRQ 4.13 4.32 3.31 3.63 5.91
ADVM's Total Ranking # 625 # 1104 # 1552 # 1504 # 1047
Seq. Current Liabilities Change -13.66 % -35.18 % -4.2 % 44.12 % 12.67 %
Seq. Current Assets Change -17.52 % -15.32 % -12.87 % -11.4 % -10.62 %



Working Capital Ratio forth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 42
Healthcare Sector # 214
Overall Market # 624


Working Capital Ratio Statistics
High Average Low
120.44 31.6 3.31
(Mar 31 2018)   (Jun 30 2023)




Financial Statements
Adverum Biotechnologies Inc 's Current Liabilities $ 25 Millions Visit ADVM's Balance sheet
Adverum Biotechnologies Inc 's Current Assets $ 103 Millions Visit ADVM's Balance sheet
Source of ADVM's Sales Visit ADVM's Sales by Geography


Cumulative Adverum Biotechnologies Inc 's Working Capital Ratio

ADVM's Working Capital Ratio for the trailling 12 Months

ADVM Working Capital Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -22.74 % 0.82 % 45.39 % 99.99 % 51.25 %
Y / Y Current Assets TTM Growth -46.08 % -41.57 % -40.19 % -39.71 % -39.9 %
Working Capital Ratio TTM 3.75 4.15 4.74 5.93 8.11
Total Ranking TTM # 390 # 787 # 1102 # 3689 # 3619
Seq. Current Liabilities TTM Growth -13.66 % -35.18 % -4.2 % 44.12 % 12.67 %
Seq. Current Assets TTM Growth -17.52 % -15.32 % -12.87 % -11.4 % -10.62 %


On the trailing twelve months basis In spite of the year on year decrease in ADVM's Current Liabilities to $24.91 millions, cumulative Working Capital Ratio to 3.75 below the ADVM average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 37 other companies have achieved higher Working Capital Ratio than Adverum Biotechnologies Inc . While Working Capital Ratio overall ranking has improved so far to 390, from total ranking during the twelve months ending third quarter 2023 at 787.

Explain Working Capital Ratio
How much in Current Assets ADVM´s has?
What is the value of ADVM´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 38
Healthcare Sector # 182
Within the Market # 390


trailing twelve months Working Capital Ratio Statistics
High Average Low
22.16 15.27 3.75
(Dec 31 2018)   (Dec 31 2023)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Century Therapeutics inc   9.92 $ 176.994  Millions$ 17.846  Millions
Argenx se  9.75 $ 4,123.737  Millions$ 422.993  Millions
Biontech Se  9.43 $ 21,870.576  Millions$ 2,318.960  Millions
Vir Biotechnology Inc   9.05 $ 1,588.226  Millions$ 175.407  Millions
Pharmacyte Biotech Inc   8.16 $ 61.508  Millions$ 7.539  Millions
Passage Bio inc   7.22 $ 117.959  Millions$ 16.341  Millions
Pluri Inc   7.12 $ 32.252  Millions$ 4.530  Millions
Fresh Tracks Therapeutics Inc   6.98 $ 11.552  Millions$ 1.656  Millions
Tarsus Pharmaceuticals Inc   6.93 $ 256.131  Millions$ 36.936  Millions
Black Diamond Therapeutics Inc   6.82 $ 134.034  Millions$ 19.646  Millions
Halozyme Therapeutics Inc   6.64 $ 746.424  Millions$ 112.494  Millions
Springworks Therapeutics Inc   6.41 $ 500.912  Millions$ 78.170  Millions
C4 Therapeutics Inc   6.34 $ 271.189  Millions$ 42.766  Millions
Twist Bioscience Corporation  5.98 $ 390.231  Millions$ 65.228  Millions
Inhibrx Inc   5.44 $ 295.358  Millions$ 54.249  Millions
Editas Medicine Inc   5.39 $ 340.829  Millions$ 63.217  Millions
Adma Biologics Inc   5.29 $ 257.013  Millions$ 48.579  Millions
Immunitybio inc   5.05 $ 294.084  Millions$ 58.283  Millions
Curis Inc   4.99 $ 60.908  Millions$ 12.212  Millions
Dbv Technologies S a   4.93 $ 158.915  Millions$ 32.236  Millions
Recursion Pharmaceuticals Inc   4.70 $ 438.137  Millions$ 93.171  Millions
Vericel Corporation  4.49 $ 205.631  Millions$ 45.749  Millions
Bio techne Corp  4.37 $ 590.640  Millions$ 135.231  Millions
Sophia Genetics Sa  4.16 $ 148.047  Millions$ 35.621  Millions
Adverum Biotechnologies Inc   4.13 $ 102.773  Millions$ 24.914  Millions
Immunocore Holdings Plc  3.84 $ 528.820  Millions$ 137.633  Millions
Moderna Inc   3.42 $ 10,325.000  Millions$ 3,015.000  Millions
Exelixis Inc   3.34 $ 1,317.958  Millions$ 394.277  Millions
Vaxart Inc   3.32 $ 45.536  Millions$ 13.724  Millions
Biocryst Pharmaceuticals Inc   3.31 $ 495.966  Millions$ 149.988  Millions

Date modified: 2024-03-19T10:06:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com